REFERENCE FILE
Dulaglutide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- GLP-1 receptor agonist fusion protein.
- Evidence
- Randomized studies.
- Limitations
- No weight-management indication.
- Safety
- Not recommended for severe gastroparesis.
- Formulation and route
- Subcutaneous injection.
- Approval scope
- Trulicity: specified type 2 diabetes populations.
A SECOND LOOK
A question to carry into the reading
Read this dulaglutide profile with the comparison written out in full. If a statement uses words such as “more,” “less,” or “better,” ask what sits on the other side of that comparison. Check whether the cited passage compares groups, different times, or separate reports. Those are different questions, so your notes should not quietly swap one for another. Also identify whether both sides use the same measure and period. If the comparison is incomplete, leave space for the missing details. The aim is a statement whose reference point is visible, so another reader can examine the same comparison.
Questions to keep beside the page
- What exactly is being compared, and where is that comparison defined?
- Are both sides described using the same measure and observation period?
- Does my summary preserve the comparison made in the cited passage?
Sources for this file
- TRULICITYNLM · Checked
FROM THE REFERENCE DESK